These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 37816478)

  • 21. Case report: Treatment of long COVID with a SARS-CoV-2 antiviral and IL-6 blockade in a patient with rheumatoid arthritis and SARS-CoV-2 antigen persistence.
    Visvabharathy L; Orban ZS; Koralnik IJ
    Front Med (Lausanne); 2022; 9():1003103. PubMed ID: 36213654
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structural and functional impairments of skeletal muscle in patients with postacute sequelae of SARS-CoV-2 infection.
    Colosio M; Brocca L; Gatti MF; Neri M; Crea E; Cadile F; Canepari M; Pellegrino MA; Polla B; Porcelli S; Bottinelli R
    J Appl Physiol (1985); 2023 Oct; 135(4):902-917. PubMed ID: 37675472
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SARS-CoV-2 post-acute sequelae in previously hospitalised patients: systematic literature review and meta-analysis.
    Kelly JD; Curteis T; Rawal A; Murton M; Clark LJ; Jafry Z; Shah-Gupta R; Berry M; Espinueva A; Chen L; Abdelghany M; Sweeney DA; Quint JK
    Eur Respir Rev; 2023 Sep; 32(169):. PubMed ID: 37437914
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prediction of Post-Acute-Sequelae of COVID-19 by Cargo Protein Biomarkers of Blood Total Extracellular Vesicles in Acute COVID-19.
    Goetzl EJ; Yao PJ; Kapogiannis D
    Am J Med; 2023 Aug; 136(8):824-829. PubMed ID: 37072092
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molnupiravir and risk of post-acute sequelae of covid-19: cohort study.
    Xie Y; Choi T; Al-Aly Z
    BMJ; 2023 Apr; 381():e074572. PubMed ID: 37161995
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Persistence of SARS CoV-2 S1 Protein in CD16+ Monocytes in Post-Acute Sequelae of COVID-19 (PASC) up to 15 Months Post-Infection.
    Patterson BK; Francisco EB; Yogendra R; Long E; Pise A; Rodrigues H; Hall E; Herrera M; Parikh P; Guevara-Coto J; Triche TJ; Scott P; Hekmati S; Maglinte D; Chang X; Mora-Rodríguez RA; Mora J
    Front Immunol; 2021; 12():746021. PubMed ID: 35082777
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-world effectiveness of COVID-19 vaccines and anti-SARS-CoV-2 monoclonal antibodies against postacute sequelae of SARS-CoV-2: analysis of a COVID-19 observational registry for a diverse US metropolitan population.
    Tannous J; Pan AP; Potter T; Bako AT; Dlouhy K; Drews A; Sostman HD; Vahidy FS
    BMJ Open; 2023 Apr; 13(4):e067611. PubMed ID: 37019490
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fatigue in post-acute sequelae of SARS-CoV2 (PASC) treated with oxygen-ozone autohemotherapy - preliminary results on 100 patients.
    Tirelli U; Franzini M; Valdenassi L; Pisconti S; Taibi R; Torrisi C; Pandolfi S; Chirumbolo S
    Eur Rev Med Pharmacol Sci; 2021 Sep; 25(18):5871-5875. PubMed ID: 34604980
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk factors associated with post-acute sequelae of SARS-CoV-2: an N3C and NIH RECOVER study.
    Hill EL; Mehta HB; Sharma S; Mane K; Singh SK; Xie C; Cathey E; Loomba J; Russell S; Spratt H; DeWitt PE; Ammar N; Madlock-Brown C; Brown D; McMurry JA; Chute CG; Haendel MA; Moffitt R; Pfaff ER; Bennett TD; ;
    BMC Public Health; 2023 Oct; 23(1):2103. PubMed ID: 37880596
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Considerations in Children and Adolescents Related to Coronavirus Disease 2019 (COVID-19).
    Chen EY; Burton JM; Johnston A; Morrow AK; Yonts AB; Malone LA
    Phys Med Rehabil Clin N Am; 2023 Aug; 34(3):643-655. PubMed ID: 37419537
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long COVID in cancer patients: preponderance of symptoms in majority of patients over long time period.
    Dagher H; Chaftari AM; Subbiah IM; Malek AE; Jiang Y; Lamie P; Granwehr B; John T; Yepez E; Borjan J; Reyes-Gibby C; Flores M; Khawaja F; Pande M; Ali N; Rojo R; Karp DD; Chaftari P; Hachem R; Raad II
    Elife; 2023 Feb; 12():. PubMed ID: 36748905
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prolonged indoleamine 2,3-dioxygenase-2 activity and associated cellular stress in post-acute sequelae of SARS-CoV-2 infection.
    Guo L; Appelman B; Mooij-Kalverda K; Houtkooper RH; van Weeghel M; Vaz FM; Dijkhuis A; Dekker T; Smids BS; Duitman JW; Bugiani M; Brinkman P; Sikkens JJ; Lavell HAA; Wüst RCI; van Vugt M; Lutter R;
    EBioMedicine; 2023 Aug; 94():104729. PubMed ID: 37506544
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune mechanisms underlying COVID-19 pathology and post-acute sequelae of SARS-CoV-2 infection (PASC).
    Mohandas S; Jagannathan P; Henrich TJ; Sherif ZA; Bime C; Quinlan E; Portman MA; Gennaro M; Rehman J;
    Elife; 2023 May; 12():. PubMed ID: 37233729
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Short-term and Long-term Rates of Postacute Sequelae of SARS-CoV-2 Infection: A Systematic Review.
    Groff D; Sun A; Ssentongo AE; Ba DM; Parsons N; Poudel GR; Lekoubou A; Oh JS; Ericson JE; Ssentongo P; Chinchilli VM
    JAMA Netw Open; 2021 Oct; 4(10):e2128568. PubMed ID: 34643720
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of SARS-CoV-2 Vaccination on Symptoms from Post-Acute Sequelae of COVID-19: Results from the Nationwide VAXILONG Study.
    Scherlinger M; Pijnenburg L; Chatelus E; Arnaud L; Gottenberg JE; Sibilia J; Felten R
    Vaccines (Basel); 2021 Dec; 10(1):. PubMed ID: 35062706
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Markers of Immune Activation and Inflammation in Individuals With Postacute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
    Peluso MJ; Lu S; Tang AF; Durstenfeld MS; Ho HE; Goldberg SA; Forman CA; Munter SE; Hoh R; Tai V; Chenna A; Yee BC; Winslow JW; Petropoulos CJ; Greenhouse B; Hunt PW; Hsue PY; Martin JN; Daniel Kelly J; Glidden DV; Deeks SG; Henrich TJ
    J Infect Dis; 2021 Dec; 224(11):1839-1848. PubMed ID: 34677601
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exploring risk factors for persistent neurocognitive sequelae after hospitalization for COVID-19.
    Ch'en PY; Gold LS; Lu Q; Ye T; Andrews JS; Patel P
    Ann Clin Transl Neurol; 2023 Jul; 10(7):1200-1208. PubMed ID: 37265172
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Brain Fog and Fatigue following COVID-19 Infection: An Exploratory Study of Patient Experiences of Long COVID.
    Chasco EE; Dukes K; Jones D; Comellas AP; Hoffman RM; Garg A
    Int J Environ Res Public Health; 2022 Nov; 19(23):. PubMed ID: 36497573
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Liquid biomarkers of macrophage dysregulation and circulating spike protein illustrate the biological heterogeneity in patients with post-acute sequelae of COVID-19.
    Schultheiß C; Willscher E; Paschold L; Gottschick C; Klee B; Bosurgi L; Dutzmann J; Sedding D; Frese T; Girndt M; Höll JI; Gekle M; Mikolajczyk R; Binder M
    J Med Virol; 2023 Jan; 95(1):e28364. PubMed ID: 36458566
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SARS-CoV-2-specific T cells associate with inflammation and reduced lung function in pulmonary post-acute sequalae of SARS-CoV-2.
    Littlefield KM; Watson RO; Schneider JM; Neff CP; Yamada E; Zhang M; Campbell TB; Falta MT; Jolley SE; Fontenot AP; Palmer BE
    PLoS Pathog; 2022 May; 18(5):e1010359. PubMed ID: 35617421
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.